ResearcherLund UniversityActive in the last 2 years

Ludivine Bertonnier‐Brouty

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1294-3244; OpenAlex author ID A5071460396. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper

Papers 2

Homeobox protein B6 and homeobox protein B8 control immune-cancer cell interactions in pancreatic cancer. Co-author DOI 10.1186/s43556-025-00292-5 ↗
E2F transcription factors promote tumorigenicity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.7187 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hanna E. Seppänen · 2 shared papers, 2024–2025 · strength 0.43
- Paper Homeobox protein B6 and homeobox protein B8 control immune-cancer cell interactions in pancreatic cancer. DOI 10.1186/s43556-025-00292-5 ↗
- Paper E2F transcription factors promote tumorigenicity in pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.7187 ↗
Isabella Artner · 2 shared papers, 2024–2025 · strength 0.43
- Paper Homeobox protein B6 and homeobox protein B8 control immune-cancer cell interactions in pancreatic cancer. DOI 10.1186/s43556-025-00292-5 ↗
- Paper E2F transcription factors promote tumorigenicity in pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.7187 ↗
Caj H. Haglund · 2 shared papers, 2024–2025 · strength 0.43
- Paper Homeobox protein B6 and homeobox protein B8 control immune-cancer cell interactions in pancreatic cancer. DOI 10.1186/s43556-025-00292-5 ↗
- Paper E2F transcription factors promote tumorigenicity in pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.7187 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.